title: [Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma].
abstract: Malignant Hodgkin's lymphoma (HL) has become a curable disease through the increasing intensity of the treatment strategies applied. These regimens are aggressive, including radiotherapy and chemotherapy leading to the possibility of secondary malignancies. The German Hodgkin Lymphoma Study Group considered three cohorts including 5,411 patients with all stages of HL. In 127 patients a secondary solid tumor was diagnosed (cumulative risk 2%, median follow-up 72 months), with bronchial carcinomas (23.6%) and colorectal adenocarcinomas (20.5%) being the most frequent neoplasms. Secondary acute myeloid leukemia was found in 36 patients, another ten developed myeloid dysplasia (cumulative risk 1%, median follow-up 55 months). A total of 52 patients revealed a non-Hodgkin's lymphoma (NHL; cumulative risk 0.9%, median follow-up 46 months). The overall incidence of secondary malignancies was 3.9% in patients who had been treated successfully for their HL with radio- and/or chemotherapy.A secondary NHL can be particularly difficult to be distinguished from the preceding HL. Therefore, in case of a suspected relapse, a complete histopathological work-up must be performed.
authors.affiliation: Klinik I für Innere Medizin, Universität zu Köln, Joseph-Stelzmannstrasse 9, 50924 Köln.
authors.forename: P
authors.initials: P
authors.lastname: Borchmann
authors.forename: K
authors.initials: K
authors.lastname: Behringer
authors.forename: A
authors.initials: A
authors.lastname: Josting
authors.forename: J U
authors.initials: JU
authors.lastname: Rueffer
authors.forename: R
authors.initials: R
authors.lastname: Schnell
authors.forename: V
authors.initials: V
authors.lastname: Diehl
authors.forename: A
authors.initials: A
authors.lastname: Engert
authors.forename: H M
authors.initials: HM
authors.lastname: Kvasnicka
authors.forename: J
authors.initials: J
authors.lastname: Thiele
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced / Q000473:pathology; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000453:epidemiology* / Q000473:pathology; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents